The Vaccine Market Broke 200 Billion. Should Anyone Be Surprised?

/by Bruce Carlson

In 2022, the global market for vaccines is estimated to reach $202.6 billion.  COVID-19 vaccines represent roughly two thirds of these revenues, according to our just-published market research report The 2022 World Market for Vaccines (https://kaloramainformation.com/product/the-2022-world-market-for-vaccines/).   Should we be surprised? Even before COVID-19, there was an increasing awareness of the role of vaccines in preventing disease. While […]

Read more

The Interplay of IVD and Vaccines

/by Bruce Carlson

Worthy of note. We’ve published reports on in vitro diagnostics and vaccines two months a part. And the two markets are not unrelated. Testing procedure volumes will relate, usually, to the occurrence of disease. Vaccines are intended to prevent disease. (Tests perform that function as well, by suggesting isolation or treatment of patients, but vaccines […]

Read more

Decline of Microarrays as RNA Sequencing Technology Surges: Report

/by Bruce Carlson

The total RNA sequencing market was estimated at $2,368 million ($2.37 billion) in 2021, with roughly 3/4 of revenues from consumables. The following table and graph present the estimates for 2021. This according to a new report from Kalorama Information on RNA Sequencing markets. The sequencing market has continued to provide powerful tools that hold […]

Read more

The Market for the Making of IVD Products is 15 Billion: Report

/by Bruce Carlson

The global in vitro diagnostic (IVD) industry incorporates a sizable contract manufacturing segment that supplies a full range of reagents and test kits, instruments and systems, and testing accessories. This according to Kalorama Information’s latest report on Contract Manufacturing in IVD: https://kaloramainformation.com/product/the-market-for-contract-manufacturing-in-in-vitro-diagnostics-ivd/. The market will grow at double the rate of the overall IVD market, […]

Read more

BCMOs: Who’s Winning?

/by Bruce Carlson

The global BCMO industry is highly fragmented, with 40 BCMOs/CDMOs accounting for roughly one quarter of the industry’s revenues and the remainder comprised of a large number of smaller players. Based upon 2021 figures, Catalent led the overall market with estimated BCMO sales of $2.2 billion It was followed closely by Cytiva with $2.0 billion […]

Read more

CMOs Thrive on New Trend: Pharma Personnel Shortages

/by Bruce Carlson

Biotechnology BCMO services, including both clinical and commercial production, were estimated at $11.9 billion in 2021. This according to the just-published Kalorama market analysis of the BCMO market. – https://kaloramainformation.com/product/biopharmaceutical-contract-manufacturing-organization-cmo-market-2022/ This segment has been expanding strongly by an estimated 13% per year since 2016, with increased growth of 15.5% per year from 2021 to 2026. […]

Read more

American College of Physicians Discourages DTC Genetic Testing

/by Bruce Carlson

A recent article in the ACP journal discourages the use of DTC genetic testing and recommends that testing be undertaken in the context of a patient-physician relationship with appropriate counseling. Physicians, healthcare systems, and others with access to patient data must safeguard the privacy, confidentiality, and security of patient information, including genomic information, ACP noted. […]

Read more

What You May Have Missed at AACC 2022: Free White Paper

/by Bruce Carlson

From a biosensor that won AACC’s disruptive technology award, to a new use for AI in IVD, to the realities of automation at real-world laboratories, this year’s AACC conference had a lot to offer. Many Kalorama customers either were not able to make the show or were at the show but may have missed a […]

Read more

IVD in India: Growing, Aging Population Impacts Healthcare

/by Daniel Granderson

India, which is expected to surpass China as the most populous country in the world by 2023, has a growing $1,482 million ($1.5 billion) in vitro diagnostics (IVD) industry that is forecast to increase through 2026, as reported by Kalorama Information in the new medical market research study, In Vitro Diagnostics (IVD) in India. The […]

Read more

Perkin Elmer Splits Analytical and IVD/Life Science Companies

/by Bruce Carlson

Perkin Elmer announced it has entered into an agreement with the intention to divest its Applied, Food and Enterprise Services businesses to New Mountain Capital, a leading growth-oriented private equity firm, for total consideration of $2.45 billion in cash, $2.30 billion of which will be received at the closing and $150 million of which will […]

Read more